Treatment-related adverse events.

aIncidence of constipation for the PTD arm was significantly higher than the PCD, PAD and PD groups (χ2 = 5.002, 12.240, 9.876, P = 0.025, <0.001, 0.002).
bIncidence of diarrhea for the PTD arm was significantly higher than the PD group (χ2 = 5.577, P = 0.048).
cIncidence of herpes zoster for the PTD arm was significantly higher than the PCD, PAD and PD groups (χ2 = 8.568, 14.552, 12.641, P = 0.003, <0.001, <0.001).
dPeripheral neuropathy of all grades was more frequently reported in patients in the PTD group compared to the other groups which was obviously higher than that of the PCD, PAD and PD groups (χ2 = 4.819, 18.848, 11.182, P = 0.028, <0.001, 0.001).
eIncidence of grade 2 to 3 peripheral neuropathy for the PTD arm was significantly higher than the PCD, PAD and PD groups (χ2 = 7.562, 14.190, 9.584, P = 0.006, <0.001, 0.002). There was no significant difference in other treatment-related adverse events among groups.